Abstract Body

Background

IgA is the most abundant antibody in humans, yet its function in viral infections, including HIV-1, is elusive. Humans have two IgA subclasses: IgA1 (with 1 allelic variant) and IgA2 (with 3 allelic variants), differing in sequence, hinge length, and glycosylation, and expressed as monomers (mIgA), dimers (dIgA), or secretory forms (sIgA). Neutralization at mucosal surfaces is believed to be the primary anti-viral mechanism of IgA. Yet, while all IgA forms have an Fc region, only mIgA is known to bind FcαRI (CD89) and mediate Antibody-Dependent Cellular Phagocytosis (ADCP) and Antibody-Dependent Cellular Cytotoxicity (ADCC). dIgA and sIgA are believed to lack significant Fc-effector function due to steric hindrance of accessible CD89 binding sites. Here we aim to provide a comprehensive structure-anti-HIV-1 Fc-function analysis of all known variants of human IgA.

Methods

mIgA, dIgA and sIgA forms of IgA1 and IgA2 were generated using the variable regions of anti-HIV-1 IgG1 antibodies: the ADCC-potent A32 and the broadly neutralizing N49P9.6. CD89 binding was evaluated by surface plasmon resonance (SPR) and fluorescence correlation spectroscopy (FCS). CD89-mediated signaling through Syk and ERK kinases phosphorylation was analyzed using multiplex Luminex assay.  ADCP of virions and ADCC of gp120-coated cells were measured using neutrophils or PBMCs as effector cells, respectively. Structures of the Fc-FcαRI complexes were solved using X-ray crystallography.

Results

We engineered and expressed all human IgA subclasses and allelic variants, along with their oligomeric forms using the variable regions of A32 and N49P9.6 IgG1. All IgA variants bound to FcαRI, with dissociation constants in the low uM range (2-5 x10−7M). All mIgA variants were capable of signaling through CD89 and mediating Fc-dependent effector functions, including ADCP and ADCC, with IgA1 showing slightly enhanced potency. Notably, we also observed evidence of ADCC activity with dimeric IgA2(m1) and ADCP activity for dIgA2(mn). Crystal structures of the Fc-FcαRI complex for mIgA1 and mIgA2(m1) revealed slight differences in the formation of the binding interfaces.

Conclusions

Monomeric IgA is not the only form of human IgA capable of binding to and signaling through the FcαRI (CD89) receptor. Our findings indicate that oligomeric forms of IgA can also interact with CD89 and mediate Fc-effector activities, providing new insights into biological roles of IgA, the most abundant Ab isotype in the human immune system.